Cumulus Neuroscience and Transpharmation have partnered to align EEG and behavioural measures from preclinical CNS research through first-in-human studies.

The companies will work with biopharma sponsors to carry quantitative EEG and behavioural endpoints from animal models into clinical and home monitoring through Cumulus’s NeuLogiq platform. A February 2026 cross-species analysis found a conserved ketamine EEG signature in mice, rats, dogs and humans, supporting EEG as a translational biomarker.